Oncology Peer Review On-The-Go: Two Experts Review Important R/R DLBCL Treatment Decisions and Data

, ,

Gilles Salles, MD, PhD, and Kami Maddocks, MD, discuss relapsed/refractory diffuse large B-cell lymphoma therapeutic options and important data from the L-MIND trial.

For the final installment of our 3-part relapsed/refractory DLBCL podcast series, CancerNetwork® heard from Gilles Salles, MD, PhD, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center in New York, and Kami Maddocks, MD, an associate professor of clinical internal medicine in the Division of Hematology at The Ohio State University Wexner Medical Center, on treatment strategies for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

These experts spoke about on data regarding tafasitamab (Monjuvi) use in the L-MIND trial (NCT02399085), when to implement CAR-T cell therapies, the role of selinexor (Xpovio), and other important ideas.

Don’t forget to subscribe to the Oncology Peer Review On-The-Go podcast on Apple Podcasts, Spotify, or anywhere podcasts are available. Be sure to check out the 2 other installments of this 3-part DLBCL series on rituximab rechallenging and different treatment regimens for DLBCL.